HomeProductsBioactive CompoundsProtein Kinase Targetsc-Met/HGFRTivantinib
Chemical structure of CAS 905854-02-6

Tivantinib

CAS No.905854-02-6
MDL No.MFCD11977597
MFC23H19N3O2
MW369.40
InChI KeyUCEQXRCJXIVODC-PMACEKPBSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

LSM-1131 is an indole derivative.

CAS No.905854-02-6
Product NameTivantinib

Biological Targets

MET

Associated Conditions

non-small cell lung carcinoma·triple-negative breast cancer·hepatocellular carcinoma·cancer·malignant pleural mesothelioma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.

Nature genetics • Vol. 50, Issue 7 • 2018
PMID: 29915428PMC: PMC6421579DOI: 10.1038/s41588-018-0138-4

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 19, Issue 15 • 2013
PMID: 23766362DOI: 10.1158/1078-0432.CCR-13-1321

Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.

Cancer research • Vol. 73, Issue 10 • 2013
PMID: 23598276PMC: PMC3759033DOI: 10.1158/0008-5472.CAN-12-3256

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 29, Issue 24 • 2011
PMID: 21768463DOI: 10.1200/JCO.2010.34.0570

Documentation

Similar Products